News for Genmab A/S (GNMSF)

**media[653452]**

**media[650522]**

Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective response rate (ORR) of...

Rinatabart sesutecan (Rina-S®) showed a 50% objective response rate in advanced endometrial cancer patients during the Phase 1/2 RAINFOLâ„¢-01 trial. T

**media[638247]**

**media[637000]**

Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30...

Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 to June 3 in Chicago. Key highlights include the first public results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate […]

[url="]Genmab A/S[/url] (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage p

**media[634775]**

**media[633186]**

[url="]Genmab A/S[/url] (Nasdaq: GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administ

**media[625899]**

May 08, 2025 / 04:00PM GMTOperator Hello and welcome to the Genmab financial results conference call for the first quarter of 2025. As a reminder, this conferen

**media[619369]**

We recently published a list of 13 Most Profitable Growth Stocks to Buy Now.

The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the market.

Baron International Growth Fund increased in the first quarter of 2025, although it underperformed its benchmark, the MSCI ACWI ex USA Index. Read more here.

**media[607500]**